List of Benchling Bioresearch Customers
Benchling
680 Folsom St., 8th Floor,
San Francisco, 94107, CA,
United States
San Francisco, 94107, CA,
United States
1 415-590-2798
Professional Services
900
$200M
Since 2010, our global team of researchers has been studying Benchling Bioresearch customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Benchling Bioresearch for Laboratory Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Benchling Bioresearch for Laboratory Management include: AstraZeneca, a United Kingdom based Life Sciences organisation with 94300 employees and revenues of $73.98 billion, Sanofi, a France based Life Sciences organisation with 82878 employees and revenues of $47.74 billion, Gilead Sciences, a United States based Life Sciences organisation with 17600 employees and revenues of $28.75 billion, Syngenta, a Switzerland based Life Sciences organisation with 30000 employees and revenues of $16.98 billion, Moderna, a United States based Life Sciences organisation with 5600 employees and revenues of $6.75 billion and many others.
Contact us if you need a completed and verified list of companies using Benchling Bioresearch, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Benchling Bioresearch customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Adaptive Biotechnologies | Life Sciences | 790 | $185M | United States | Benchling | Benchling Bioresearch | Laboratory Management | 2024 | n/a |
In 2024 Adaptive Biotechnologies implemented Benchling Bioresearch as their Laboratory Management platform to centralize high-throughput molecular research operations. The deployment targeted Adaptive's molecular research teams working with NGS and PCR, establishing Benchling Bioresearch as the primary system for assay orchestration and data management.
Benchling Bioresearch was configured with Benchling Connect to automate common Laboratory Management functions, including sample and reagent registration, template generation, and results capture. The implementation leveraged Benchling Registry and Results schemas to standardize metadata and instrument outputs, and Benchling Connect was used to auto-generate and format metadata CSVs required for downstream omics pipelines.
Integrations were implemented directly with Hamilton liquid handlers and other lab instruments to enable bi-directional data flow between instruments and Benchling. Instrument output was funneled into Benchling Registry and Results, pre-formatted for NGS analysis to remove manual reformatting and to reduce mismatches that previously disrupted downstream pipelines.
Operationally the rollout removed manual CSV and template building, and it automated sample routing and instrument job submission to reduce copy and paste handoffs. Governance was concentrated on standardized metadata schemas and instrument orchestration within Benchling, shifting troubleshooting and weekly audit effort into automated validation and traceability workflows.
Measured outcomes reported by Adaptive are explicit, including weekly file-handling mistakes dropping to nearly zero saving the team over 20 hours a month, faster resolution of data issues, and scientists spending more time on discovery. NGS workflow throughput increased nearly 1.5x, and every dataset became fully traceable and immediately shareable, making Benchling Bioresearch integral to Adaptive Biotechnologies Laboratory Management and molecular research operations.
|
 |
Arbor Biotechnologies | Life Sciences | 114 | $1M | United States | Benchling | Benchling Bioresearch | Laboratory Management | 2024 | n/a |
In 2024, Arbor Biotechnologies deployed Benchling Bioresearch as their Laboratory Management platform for next-generation sequencing and research data management. The engagement began on Benchling's free plan as a central source of truth for NGS data, and Arbor upgraded the tenancy shortly after to broaden access across research teams.
Benchling Bioresearch was configured to enforce structured and consistent data submission workflows, implementing mandatory metadata fields and standardized experiment records to improve traceability. Functional capabilities implemented include NGS data management, automated workflow orchestration for sequencing processes, and centralized experiment and sample recordkeeping aligned to Laboratory Management best practices. These configurations reduced friction in data capture and enabled researchers to navigate complex datasets more consistently.
Operational scope focused on Arbor's R&D organization and sequencing groups, bringing multiple teams onto a unified research data platform. Collaboration workflows and shared record access were established to streamline handoffs between assay development, sequencing operations, and analysis teams. Role-based access controls and centralized record authoring supported governance of experimental records and specimen provenance.
Governance changes included standardized procedures, mandatory fields driving data quality, and automated routing for sequencing workflows to accelerate troubleshooting and improve traceability. Arbor reported smoother collaboration, increased throughput, better resource utilization, and faster identification and resolution of errors across NGS operations as outcomes of the rollout. The deployment positions Benchling Bioresearch as the central Laboratory Management system underpinning Arbor Biotechnologies research processes.
|
 |
AstraZeneca | Life Sciences | 94300 | $74.0B | United Kingdom | Benchling | Benchling Bioresearch | Laboratory Management | 2022 | n/a |
In 2022, AstraZeneca implemented Benchling Bioresearch as its Laboratory Management platform to automate and scale DNA construct design and assembly for early drug discovery workflows. The initiative was led by an internal team in Sweden and extended operational support to research teams across Sweden and the U.K., focusing on recombinant protein production, cell line engineering, and in vitro screening use cases.
The Benchling Bioresearch deployment centralized several functional capabilities, including an automated sequence search, algorithmic fragmentation and codon optimization, multiple sequence alignment, and pooling instruction generation for downstream assembly. Benchling Bioresearch was configured to capture pooling files, pooling-to-construct mappings, and QC metadata such as plasmid purity and concentration, enabling the platform to serve as a single source of truth for sample management and DNA assembly traceability.
AstraZeneca integrated its FRAGLER fragment recycling algorithm into Benchling via the Benchling developer platform and open APIs, enabling automated identification and reuse of preexisting fragments. The automated pipeline connects to in-house tooling and lab automation, including placement of layout files and liquid handling instructions for external DNA synthesis, pooling of de novo synthesized DNA with parts from an internal Biostore, assembly on an ECHO 655T integrated on an Access system, automated cloning and extraction using a Biomek i7 with an integrated colony picker, and sequence validation by Sanger sequencing.
Governance and rollout were driven by an in-house design and request portal that feeds global requests into the Benchling workflow, with an initial configuration effort followed by rapid adoption. Outcomes documented in the deployment include decreased end-to-end plasmid generation timelines from 4 to 8 weeks down to about 3 weeks, fragment recycling that yielded a 55.3% base pair recycle rate and 62,974 nucleotides recycled, and reported cost reductions ranging from 50 to 90 percent for DNA synthesis through fragment reuse. AstraZeneca continues to instrument Benchling Bioresearch to track timelines and cost savings within the platform to support ongoing campaign-based recycling and scale.
|
 |
Cambrium | Life Sciences | 23 | $1M | Germany | Benchling | Benchling Bioresearch | Laboratory Management | 2024 | n/a |
In 2024, Cambrium implemented Benchling Bioresearch as its centralized Laboratory Management platform to standardize experiment capture and support protein biomaterials R&D. Cambrium is a Berlin Germany based industrial biotech firm using molecular design and precision fermentation to produce micro-molecular collagen, and the Benchling Bioresearch deployment was positioned to unify data capture across its laboratory operations.
The implementation focused on structured data capture, experiment workflow configuration, and a centralized laboratory database to enable AI ready datasets. Benchling Bioresearch was configured to capture instrument output and scientist annotations in a common data model, and to support automated ML feedback loops from protein design through candidate identification. Functional capabilities implemented included experiment and protocol management, inventory and sample tracking, and searchable assay records to drive repeatable workflows.
Integrations emphasized instrument connectivity and data pipeline ingestion, making Benchling Bioresearch the primary route for laboratory-generated data. The platform was used across Cambrium’s wet lab and dry lab practices from the organization’s inception, enabling pipelines to consume Benchling’s database directly and permitting rapid plugging in of AI models. This created a single source of truth for lab measurements and experiments, preventing parallel data journeys and improving data retrievability for modeling and analytics.
Governance changes accompanied the rollout, with a common language established between scientists and instruments and organization wide alignment on data structures and capture practices. Onboarding and process training shifted teams toward data centric experiment design, and Benchling’s unified records helped accelerate cross functional collaboration. Explicit outcomes reported by Cambrium included improved data quality, faster milestones through AI and ML feedback loops, reduced costs via faster onboarding and IT efficiencies, and a tenfold improvement in protein synthesis capabilities within the lab.
|
 |
Cue Biopharma | Life Sciences | 57 | $15M | United States | Benchling | Benchling Bioresearch | Laboratory Management | 2023 | n/a |
In 2023, Cue Biopharma deployed Benchling Bioresearch as its Laboratory Management platform to create a structured and traceable data foundation across process development. Cue Biopharma is a clinical-stage company developing injectable biologics that modulate disease-relevant T cells, and the Benchling Bioresearch implementation was positioned to accelerate advancement of drug candidates through process development into the clinic.
The implementation consolidated capabilities for process design, execution, and analysis, alongside centralized sample tracking and complete sample history recording. Configured, adaptable data schemas and entity models were implemented to capture sample name, location, history, and results, allowing teams to record full experimental context without extensive model rewrites. Automation was applied to manage completed steps and batch handoffs, enabling sequential workflow orchestration across laboratory operations.
Operational coverage included research and development, process development, analytical operations, and CMC digital strategy, supporting cross-functional scientist collaboration. The system coordinated samples and data transfers for over 4000 engineered constructs, and data structures were developed so information could be shared with external partners such as contract testing labs. By retaining discovery and process data in the same environment, Benchling Bioresearch supported seamless knowledge transfer between functional teams.
Governance and process changes emphasized a streamlined request system to reduce ad hoc status inquiries, standardized sample metadata and unified capture protocols to improve handoffs, and persistent sample lineage for traceability. Role based controls and audit oriented capture were applied to support operational discipline and regulatory readiness while allowing on the fly modifications to data models to accommodate evolving experimental methods.
Outcomes reported by Cue Biopharma include accelerated process development timelines, improved collaboration and handoffs between research and development, and increased innovation enabled by adaptable data structures. Benchling Bioresearch provided a unified Laboratory Management environment that shortened process development cycles and surfaced longitudinal result trends to support faster decision making.
|
 |
|
Life Sciences | 107 | $35M | United States | Benchling | Benchling Bioresearch | Laboratory Management | 2023 | n/a |
|
|
|
|
Professional Services | 250 | $45M | United States | Benchling | Benchling Bioresearch | Laboratory Management | 2022 | n/a |
|
|
|
|
Life Sciences | 10 | $3M | Denmark | Benchling | Benchling Bioresearch | Laboratory Management | 2024 | n/a |
|
|
|
|
Life Sciences | 17600 | $28.8B | United States | Benchling | Benchling Bioresearch | Laboratory Management | 2023 | n/a |
|
|
|
|
Professional Services | 41 | $5M | United Kingdom | Benchling | Benchling Bioresearch | Laboratory Management | 2022 | n/a |
|
Showing 1 to 10 of 22 entries
Buyer Intent: Companies Evaluating Benchling Bioresearch
ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Benchling Bioresearch. Gain ongoing access to real-time prospects and uncover hidden opportunities.
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||
FAQ - APPS RUN THE WORLD Benchling Bioresearch Coverage
Benchling Bioresearch is a Laboratory Management solution from Benchling.
Companies worldwide use Benchling Bioresearch, from small firms to large enterprises across 21+ industries.
Organizations such as AstraZeneca, Sanofi, Gilead Sciences, Syngenta and Moderna are recorded users of
Benchling Bioresearch for Laboratory Management.
Companies using Benchling Bioresearch are most concentrated in Life Sciences, with adoption spanning over 21 industries.
Companies using Benchling Bioresearch are most concentrated in United Kingdom, France and United States, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Benchling Bioresearch across Americas, EMEA, and APAC.
Companies using Benchling Bioresearch range from small businesses with 0-100 employees - 27.27%, to mid-sized firms with 101-1,000 employees - 45.45%, large organizations with 1,001-10,000 employees - 4.55%, and global enterprises with 10,000+ employees - 22.73%.
Customers of Benchling Bioresearch include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.
Contact APPS RUN THE WORLD to access the full verified Benchling Bioresearch customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Laboratory Management.